젤-seq: DNA와 RNA 히드로 매트릭스를 사용 하 여 동시 시퀀싱 라이브러리 준비를 위한 방법

Executive Industry Relevance

Gel-seq enables simultaneous DNA and RNA library preparation from small cell populations without sample splitting, addressing a key bottleneck in multi-omics discovery workflows. This capability supports target validation by linking genomic structural variations to transcriptional responses in disease-relevant systems, enhancing predictive confidence in early-stage R&D. The method’s compatibility with standard electrophoresis equipment and low input requirements (100–1000 cells) facilitates scalable adoption in preclinical screening and biomarker discovery pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by correlating DNA copy number variations with gene expression changes in the same cellular context.
• Operational Value: Eliminates sample splitting, reducing variability and preserving biological fidelity for target de-risking.
• Scientific Value: Supports functional validation of genomic targets through paired genomic-transcriptomic readouts from identical samples.

Screening & Assay Development

• Scientific Value: Produces standardized, quantitative nucleic acid outputs suitable for assay normalization and cross-platform comparison.
• Operational Value: Uses familiar WTA and library prep kits, minimizing training overhead and enabling rapid integration into existing genomics workflows.
• Scientific Value: Generates reproducible fragment distributions comparable to standard methods, ensuring data reliability for screening campaigns.

Translational & Preclinical Research

• Scientific Value: Maintains continuity from discovery through preclinical validation by preserving native DNA-RNA relationships in disease models.
• Operational Value: Adaptable to standard gel cassettes, allowing seamless transfer across labs and core facilities without specialized equipment.
• Scientific Value: Provides mechanistic de-risking by enabling direct observation of how structural variants influence expression profiles in relevant systems.

Pipeline & Workflow Integration

Gel-seq fits within the early discovery continuum, supporting hypothesis-driven target validation and enabling scalable input into lead identification through multi-omic profiling.

• Discovery Biology: Facilitates hypothesis testing by linking structural DNA alterations to transcriptional outcomes without sample division.
• Screening: Delivers assay-ready, quantitative DNA and RNA libraries with consistent fragmentation profiles for reliable compound screening.
• Analytics: Generates paired-end sequencing data allowing integrated analysis of copy number variation and expression changes.
• Translational Research: Preserves biological context from primary samples through preclinical models, supporting biomarker alignment.
• Enterprise Reuse: Leverages widely available electrophoresis infrastructure, positioning Gel-seq as a reusable, low-barrier capability across discovery teams.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in genotype-phenotype relationships.
• Operational Value: Enhances reproducibility through standardized hydrogel-based separation and minimal hands-on variability.
• Strategic Value: Improves go/no-go decision quality by enabling earlier, more biologically grounded target prioritization.
• Portfolio Impact: Supports risk-adjusted advancement by providing multi-omic evidence from limited, precious samples.

Implementation Considerations

• Requires molecular biology expertise in nucleic acid handling and gel-based techniques.
• Depends on standard gel electrophoresis chambers, power supplies, and UV crosslinking equipment.
• Necessitates cross-team standardization of gel preparation and fractionation protocols.
• Involves handling neurotoxic acrylamide precursors, requiring fume hood use and safety training.
• Performance may vary with input quality and gel polymerization consistency, necessitating QC steps.

Biopharma FAQs